Gastroenterology Preclinical Deal Benchmarks (2026)

Understanding Gastroenterology Deal Benchmarks at Preclinical

Preclinical Gastroenterology licensing deals command a median upfront payment of $51M, with values ranging from $17M at the low end to $90M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the gastroenterology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $291M to $1.1B, with a median of $693M. Royalty rates for gastroenterology assets at this stage typically fall between 4.3% and 8.6% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.